DDInter1055 DDInter1435
Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic [ofloxacin]. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along with other quinolones such as [gatifloxacin] and [moxifloxacin], is a member of the third generation of fluoroquinolones, colloquially referred to as the "respiratory quinolones" due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.[A31453,A190756] Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Levofloxacin {u} (Compound) resembles {v} (Compound) Enoxacin
Levofloxacin {u} (Compound) resembles {v} (Compound) Sparfloxacin
Levofloxacin {u} (Compound) binds {v} (Gene) ABCB1
Levofloxacin {u} (Compound) upregulates {v} (Gene) CPVL
Levofloxacin {u} (Compound) palliates {v} (Disease) chronic obstructive pulmonary disease
Levofloxacin {u} (Compound) is included by {v} (Pharmacologic Class) Quinolones
Levofloxacin {u} (Compound) downregulates {v} (Gene) TRIB3
Levofloxacin {u} (Compound) causes {v} (Side Effect) Dysphagia
Levofloxacin (Compound) resembles Enoxacin (Compound)
Levofloxacin (Compound) resembles Sparfloxacin (Compound)
Levofloxacin (Compound) binds ABCB1 (Gene)
Levofloxacin (Compound) upregulates CPVL (Gene)
Levofloxacin (Compound) palliates chronic obstructive pulmonary disease (Disease)
Levofloxacin (Compound) is included by Quinolones (Pharmacologic Class)
Levofloxacin (Compound) downregulates TRIB3 (Gene)
Levofloxacin (Compound) causes Dysphagia (Side Effect)